Hyperkinetic Movement Disorders
Conditions
Keywords
chorea, dyskinesia, hyperkinetic
Brief summary
Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Detailed description
The purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Interventions
DRUGtetrabenazine
25 mg titrated to optimal dose per patient
Sponsors
Joseph Jankovic
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment. * Willing to sign informed consent. * Willing to comply with procedures required as part of this study.
Exclusion criteria
* Those subjects unwilling to comply with study requirements. * Subjects unable to give informed consent.
Outcome results
None listed